OWL Oncology Research Revenue and Competitors

Location

N/A

Total Funding

Employee Data

  • OWL Oncology Research has 13 Employees.(i)
  • OWL Oncology Research grew their employee count by 8% last year.

OWL Oncology Research's People

NameTitleEmail/Phone
1
Co-Founder, Managing Partner, Director FinanceReveal Email/Phone
2
Administrative DirectorReveal Email/Phone
3
Senior Business Operations ManagerReveal Email/Phone
4
Sr. Contract CRAReveal Email/Phone
5
Managing PartnerReveal Email/Phone
6
Managing PartnerReveal Email/Phone
7
ONCOLOGY CRA- CAR-T/ IMMUNOTHERAPYReveal Email/Phone
8
Sr. CRA Consultant at Owl OncologyReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
N/A5035%N/AN/A
#2
$7.5M128-2%N/AN/A
#3
N/A138%N/AN/A
Add Company

What Is OWL Oncology Research?

Our Mission OWL Oncology Research® is a network of Clinical Research Consultants committed to fighting the battle against cancer. Our goal is to deliver the highest quality clinical trial services to the clinical research industry. Working together, our commitment is to ensure that oncology clinical trials are conducted effectively and efficiently so that new and promising treatments become available to the millions of people battling these diseases. Commitment We are committed to facilitating the growing development needs of biotechnology companies in a world where increasingly, large conglomerated pharmaceutical / biotech companies and contract research organizations (CRO) are defining industry standards for clinical research. It is our standard and privilege to ensure that promising oncology therapeutics under development at smaller companies are granted the attention, respect, and experienced teams that they deserve, without the cost or intimidation of a large CRO.

keywords:N/A

N/A

Total Funding

13

Number of Employees

N/A

Revenue (est)

8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.1M13-7%N/A
#2
$0.8M138%N/A
#3
$2M130%N/A
#4
$1.4M13-28%N/A
#5
N/A138%N/A